Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: Relationships with serum markers of oxidation and inflammation

HIV Medicine

Volumn 11, Issue 4, 2010, Pages 225-231

  Parra, S ^a   Coll, B ^a   Aragones G ^a   Marsillach, J ^a   Beltran R ^a   Rull, A ^a   Joven, J ^a   Alonso Villaverde, C ^a   Camps, J ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Cardiovascular disease; Inflammation; Lipoproteins; Risk factors

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CALCULATION; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SCORING SYSTEM;

EID: 77950805699     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00766.x     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Grinspoon SK. Medical Progress: cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
3. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:51-58.
4. Schwarz B. Oxidative stress during viral infection: a review. Free Rad Biol Med 1996, 21:641-649.
5. Friis-Møller N, Reiss P, Sabin CA. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl Med 2007, 356:1723-1735.
6. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008, 49:S79.
7. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. The clinical epidemiology group from the French hospital database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17:2479-2486.
8. Stone NJ, Bilek S, Rosenbaum S. Recent national cholesterol education program adult treatment panel III update: adjustments and options. Am J Cardiol 2005, 96:53E-59E.
9. Dubé MP, Stein JH, Aberg JA. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medical association of the infectious disease society of America and the adult AIDS clinical trials group. Clin Infect Dis 2003, 37:613-627.
10. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER trial. Circulation 2009, 119:2026-2031.
11. Worm SW, De Wit S, Weber R. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation 2009, 119:805-811.
12. De Socio GV, Parruti G, Quirino T. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008, 57:33-40.
13. Knobel H, Jericó C, Montero M. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007, 21:452-457.
14. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004, 23:625-630.
15. Grinspoon SK, Grunfeld C, Kotler DP. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Executive summary. Circulation 2008, 118:198-210.
16. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
17. Hsue PY, Lo JC, Franklin A. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109:1603-1608.
18. Coll B, Parra S, Alonso-Villaverde C. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007, 38:2477-2484.
19. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47:C19-C31.
20. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
21. Alonso-Villaverde C, Coll B, Parra S. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004, 110:2204-2209.
22. Coll B, Parra S, Alonso-Villaverde C. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 2006, 34:51-55.
23. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006, 17:502-509.
24. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154.
25. Tward A, Xia YR, Wang XP. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
26. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004, 318:680-683.
27. Parra S, Alonso-Villaverde C, Coll B. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 2006, 7:24-31.
28. Gómez F, Camps J, Simó JM, Ferré N, Joven J. Agreement study methods based on the elimination principle for the measurement of LDL-and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clin Chem 2000, 46:118-191.
29. Ferré N, Camps J, Prats E. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48:261-268.
30. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1812-1818.
31. Stein JH, Korcarz CE, Hurst RT. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008, 21:96-111.
32. Hennerici MG, Meairs S, Adams H. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007, 23:75-80.
33. Law MG, Friis-Møller N, El-Sadr WM. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006, 7:218-230.
34. Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation 2009, 119:770-772.